0001104659-15-079964.txt : 20151118 0001104659-15-079964.hdr.sgml : 20151118 20151118163048 ACCESSION NUMBER: 0001104659-15-079964 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20151112 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20151118 DATE AS OF CHANGE: 20151118 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SUPERNUS PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001356576 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35518 FILM NUMBER: 151241123 BUSINESS ADDRESS: STREET 1: 1550 E GUDE DR CITY: ROCKVILLE STATE: MD ZIP: 20850 BUSINESS PHONE: 301-838-2500 MAIL ADDRESS: STREET 1: 1550 E GUDE DR CITY: ROCKVILLE STATE: MD ZIP: 20850 8-K 1 a15-23594_18k.htm 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 12, 2015

 

Supernus Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware

(State or other jurisdiction of
Incorporation)

 

001-35518

 

20-2590184

(Commission File Number)

 

(IRS Employer Identification No.)

 

 

 

1550 East Gude Drive, Rockville MD

 

20850

(Address of principal executive offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code: (301) 838-2500

 

Not Applicable

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


 

Item 8.01                                           Other Events.

 

On November 12, 2015, Supernus Pharmaceuticals, Inc issued a press release announcing that it had received notice that, effective following the close of trading on November 11, 2015, New Enterprise Associates distributed an aggregate of 3,820,625 shares of Supernus Pharmaceuticals common stock to its limited partners.  A copy of this press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.

 

Item 9.01                                           Financial Statements and Exhibits.

 

(d)                                 Exhibits

 

The following documents are furnished as Exhibits pursuant to Item 8.01 hereof:

 

Exhibit 99.1 — Press Release Dated November 12, 2015

 

2


 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

SUPERNUS PHARMACEUTICALS, INC.

 

 

DATED: November 18, 2015

 

By:

/s/ Gregory S. Patrick

 

 

Gregory S. Patrick

 

 

Vice-President and Chief Financial Officer

 

3


 

EXHIBIT INDEX

 

Number

 

Description

 

 

 

 

 

 

 

99.1

 

Press Release Dated November 12, 2015.

 

Attached

 

4

 EX-99.1 2 a15-23594_1ex99d1.htm EX-99.1

Exhibit 99.1

 

 

Supernus Announces Distribution of Common Stock by NEA

 

ROCKVILLE, Md., November 12, 2015 — Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that it has received notice that, effective following the close of trading on November 11, 2015, New Enterprise Associates (NEA) distributed an aggregate of 3,820,625 shares of Supernus Pharmaceuticals common stock to its partners. “The distribution announced today is a continuation of the actions NEA took in June 2015 to distribute a portion of its position to its limited partners after holding that position for over nine years,” stated Jack Khattar, president and chief executive officer of Supernus. The NEA funds continue to hold 3,820,625 shares.

 

About Supernus Pharmaceuticals, Inc.

 

Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company has two marketed products for epilepsy, Oxtellar XR® (extended-release oxcarbazepine) and Trokendi XR® (extended-release topiramate). The Company is also developing several product candidates to address large market opportunities in psychiatry, including SPN-810 for the treatment of impulsive aggression in patients with ADHD in conjunction with standard ADHD treatment, and SPN-812 for ADHD.

 

CONTACT:

 

Jack A. Khattar, President and CEO

Gregory S. Patrick, Vice President and CFO

Supernus Pharmaceuticals, Inc.

Tel: (301) 838-2591

 

Or

 

Investor Contact:

Peter Vozzo

Westwicke Partners

Office: (443) 213-0505

Mobile: (443) 377-4767

Email: peter.vozzo@westwicke.com

 

 GRAPHIC 3 g235941mmi001.jpg GRAPHIC begin 644 g235941mmi001.jpg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end